Clinical Trial Update: Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of single doses of CHF 4226 pMDI in chronic obstructive pulmonary disease (COPD) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF 4226

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED